ScreenerHero

BBIO BridgeBio Pharma, Inc.

NAS · US · Healthcare · Biotechnology · bridgebio.com
66.14USD-1.65%Mkt Cap: 12.93B $P/E: —

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR sta…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap12.93B USD
Enterprise Value15.81B USD
Revenue (TTM)713.07M USD
Gross Profit481.11M USD
Net Income (TTM)-724.93M USD
Revenue/Share3.67 USD
Last Price66.14 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees999
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)2448.13
PEG—
EV/EBITDA-33.44
EV/Revenue22.17
P/S18.44
P/B-5.22
EPS (TTM)-3.56
EPS (Forward)0.03
52W Range
48.7839% of range93.42
52W High93.42 USD
52W Low48.78 USD
Profitability
Gross Margin95.82%
Oper. Margin-43.94%
EBITDA Margin-66.30%
Profit Margin-144.39%
ROE34.74%
ROA-77.45%
Growth
Revenue Growth120.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-445.91M USD
CapEx (TTM)9.59M USD
FCF Margin-44.91%
FCF Yield-2.48%
Net Debt2.65B USD
Net Debt/EBITDA-5.61
Balance Sheet
Debt/Equity-0.89
Current Ratio1.23
Quick Ratio1.09
Book Value/Sh-12.88 USD
Cash/Share3.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)109.10 USD
Upside (mean)+64.9%
Target Range80.00 USD – 157.00 USD
80.00+64.9% to mean157.00
# Analysts21
Ownership
Shares Out.195.49M
Float167.19M
Insiders3.91%
Institutions99.52%
Short Interest
Short Ratio10.6d
Short % Float12.31%
Short % Out.11.02%
Shares Short21.55M
Short (prev mo.)23.32M
Technical
SMA 5076.32 (-13.3%)
SMA 20073.58 (-10.1%)
Beta0.97
S&P 52W Chg14.58%
Avg Vol (30d)2.53M
Avg Vol (10d)3.26M
Technical Indicators
RSI (14)34.8
MACD-3.0803
MACD Signal-3.2211
MACD Hist.+0.1408
BB Upper76.89 USD
BB Middle69.27 USD
BB Lower61.66 USD
BB Width21.98%
ATR (14)2.575 USD
Vol Ratio (20d)0.77x